-
Mashup Score: 0
This study examined retinopathy of prematurity (ROP) re-treatment rates following initial ROP treatment with anti-VEGF therapy (ranibizumab or bevacizumab) at various doses.
Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 2Updates in Retinopathy of Prematurity (ROP) - 11 month(s) ago
Drs. Michael Chiang, R. V. Paul Chan, and J. Peter Campbell, members of the Imaging and Informatics in Retinopathy of Prematurity (i-ROP) Research Consortium, discuss the latest advances in ROP screen
Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0
The proportion of premature infants diagnosed with ROP increased from 4.4% in 2003 to 8.1% in 2019, particularly among underserved populations.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity - 1 year(s) ago
Objective This study aimed to evaluate the preference for antivascular endothelial growth factor (anti-VEGF) versus laser ablation therapy as primary and additional treatment in aggressive retinopathy of prematurity (ROP) and type 1 ROP. Methods This multicentre retrospective study was conducted at nine medical centres across South Korea. A total of 94 preterm infants with ROP who underwent…
Source: BMJ Open OphthalmologyCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0ROP Protection - 1 year(s) ago
A nanoparticle based therapy for retinopathy of prematurity
Source: The OphthalmologistCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0The Algorithms of Power: Part Two - 1 year(s) ago
Gurus of ophthalmic AI – Linda Zangwill, Michael F. Chiang, and Damien Gatinel – consider where and how the technology can help deliver the highest quality eye care
Source: The OphthalmologistCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 1Current Issue Table of Contents: Ophthalmology - 1 year(s) ago
Editorial BoardPublished in issue: December 2022A3PDF ContentsPublished in issue: December 2022A5PDF This Issue at a GlanceSandeep RavindranPublished in issue: December 2022p1335Full-Text HTMLPDF A Simple Vista en Este NúmeroSandeep RavindranPublished in issue: December 2022e1-e2Full-Text HTMLPDF 期刊一览Sandeep RavindranPublished in…
Source: www.aaojournal.orgCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 3ROP: Treating and preventing blindness in preterm babies - 2 year(s) ago
Retinopathy of prematurity expert C. Armitage Harper, III, MD, of the Austin Retina Associates in Austin, Texas, discusses his experience in treating ROP cases across the globe, and his mission to prevent pre-term blindness in infants.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 2Week in review: Dry AMD research, injection safety protocols, glaucoma patients favor teleophthalmology - 2 year(s) ago
This week in the news, the University of Michigan receives a grant for dry AMD research, protocols can improve intravitreal injection safety, and asynchronous teleophthalmology is embraced by patients
Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 2
Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
If you've treated #ROP with ranibizumab or bevacizumab, you may need to re-treat the patient. https://t.co/iuA5aYzE0i #pediatrics